Beyond Air (XAIR)
Market Price (5/6/2026): $0.5702 | Market Cap: $4.9 MilSector: Health Care | Industry: Life Sciences Tools & Services
Beyond Air (XAIR)
Market Price (5/6/2026): $0.5702Market Cap: $4.9 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 129% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -71% Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. | Weak multi-year price returns2Y Excs Rtn is -141%, 3Y Excs Rtn is -174% | Penny stockMkt Price is 0.6 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -29 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -420% Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 239% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 72% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -291%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -320% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -624% High stock price volatilityVol 12M is 196% Key risksXAIR key risks include [1] severe financial distress characterized by a high cash burn rate and expensive debt, Show more. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 129% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -71% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. |
| Weak multi-year price returns2Y Excs Rtn is -141%, 3Y Excs Rtn is -174% |
| Penny stockMkt Price is 0.6 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -29 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -420% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 239% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 72% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -291%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -320% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -624% |
| High stock price volatilityVol 12M is 196% |
| Key risksXAIR key risks include [1] severe financial distress characterized by a high cash burn rate and expensive debt, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Beyond Air (XAIR) stock has lost about 50% since 1/31/2026 because of the following key factors:
1. Termination of NeuroNOS Sale Agreement. On March 10, 2026, Beyond Air announced the termination of its agreement to sell 85% of its NeuroNOS subsidiary to XTL Biopharmaceuticals Ltd.. This development eliminated a potential cash inflow of up to $32.5 million in milestone-based contingent payments and 19.9% of XTL's issued share capital, which had been announced on January 13, 2026. The termination likely negatively impacted investor confidence regarding future financial liquidity and strategic direction.
2. Nasdaq Minimum Bid Price Non-Compliance and Delisting Risk. Beyond Air received a notice from Nasdaq on April 10, 2026, indicating non-compliance with the exchange's $1.00 minimum bid price requirement for continued listing. While the company appealed the decision, with a hearing scheduled for May 14, 2026, this situation introduces significant uncertainty about the stock's future listing and overall corporate stability.
Show more
1. Termination of NeuroNOS Sale Agreement. On March 10, 2026, Beyond Air announced the termination of its agreement to sell 85% of its NeuroNOS subsidiary to XTL Biopharmaceuticals Ltd.. This development eliminated a potential cash inflow of up to $32.5 million in milestone-based contingent payments and 19.9% of XTL's issued share capital, which had been announced on January 13, 2026. The termination likely negatively impacted investor confidence regarding future financial liquidity and strategic direction.
2. Nasdaq Minimum Bid Price Non-Compliance and Delisting Risk. Beyond Air received a notice from Nasdaq on April 10, 2026, indicating non-compliance with the exchange's $1.00 minimum bid price requirement for continued listing. While the company appealed the decision, with a hearing scheduled for May 14, 2026, this situation introduces significant uncertainty about the stock's future listing and overall corporate stability.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -51.3% change in XAIR stock from 1/31/2026 to 5/5/2026 was primarily driven by a -44.6% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5052026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.19 | 0.58 | -51.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 6 | 7 | 19.3% |
| P/S Multiple | 1.3 | 0.7 | -44.6% |
| Shares Outstanding (Mil) | 6 | 9 | -26.2% |
| Cumulative Contribution | -51.3% |
Market Drivers
1/31/2026 to 5/5/2026| Return | Correlation | |
|---|---|---|
| XAIR | -51.3% | |
| Market (SPY) | 3.6% | 18.4% |
| Sector (XLV) | -5.7% | 33.9% |
Fundamental Drivers
The -71.8% change in XAIR stock from 10/31/2025 to 5/5/2026 was primarily driven by a -66.6% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5052026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.06 | 0.58 | -71.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5 | 7 | 44.8% |
| P/S Multiple | 2.2 | 0.7 | -66.6% |
| Shares Outstanding (Mil) | 5 | 9 | -41.8% |
| Cumulative Contribution | -71.8% |
Market Drivers
10/31/2025 to 5/5/2026| Return | Correlation | |
|---|---|---|
| XAIR | -71.8% | |
| Market (SPY) | 5.5% | 1.0% |
| Sector (XLV) | 1.6% | 2.8% |
Fundamental Drivers
The -85.1% change in XAIR stock from 4/30/2025 to 5/5/2026 was primarily driven by a -87.3% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5052026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.90 | 0.58 | -85.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 7 | 129.0% |
| P/S Multiple | 5.7 | 0.7 | -87.3% |
| Shares Outstanding (Mil) | 4 | 9 | -48.9% |
| Cumulative Contribution | -85.1% |
Market Drivers
4/30/2025 to 5/5/2026| Return | Correlation | |
|---|---|---|
| XAIR | -85.1% | |
| Market (SPY) | 30.4% | 1.0% |
| Sector (XLV) | 5.3% | -3.1% |
Fundamental Drivers
The -99.5% change in XAIR stock from 4/30/2023 to 5/5/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5052026 | Change |
|---|---|---|---|
| Stock Price ($) | 116.60 | 0.58 | -99.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 7 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 0.7 | |
| Shares Outstanding (Mil) | 1 | 9 | -82.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2023 to 5/5/2026| Return | Correlation | |
|---|---|---|
| XAIR | -99.5% | |
| Market (SPY) | 78.7% | 9.4% |
| Sector (XLV) | 14.4% | 3.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| XAIR Return | 79% | -31% | -70% | -82% | -90% | -21% | -99% |
| Peers Return | 20% | -12% | -8% | 16% | -15% | 4% | 0% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 5% | 92% |
Monthly Win Rates [3] | |||||||
| XAIR Win Rate | 67% | 42% | 33% | 33% | 25% | 40% | |
| Peers Win Rate | 52% | 48% | 55% | 55% | 47% | 52% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 40% | |
Max Drawdowns [4] | |||||||
| XAIR Max Drawdown | -10% | -47% | -78% | -85% | -90% | -39% | |
| Peers Max Drawdown | -13% | -35% | -31% | -15% | -23% | -12% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: LIN, APD, RMD, MASI, INSP.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/5/2026 (YTD)
How Low Can It Go
| Event | XAIR | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -37.1% | -7.8% |
| % Gain to Breakeven | 59.0% | 8.5% |
| Time to Breakeven | 103 days | 18 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -48.0% | -24.5% |
| % Gain to Breakeven | 92.1% | 32.4% |
| Time to Breakeven | 56 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -32.1% | -33.7% |
| % Gain to Breakeven | 47.2% | 50.9% |
| Time to Breakeven | 5 days | 140 days |
In The Past
Beyond Air's stock fell -37.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 59.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | XAIR | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -37.1% | -7.8% |
| % Gain to Breakeven | 59.0% | 8.5% |
| Time to Breakeven | 103 days | 18 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -48.0% | -24.5% |
| % Gain to Breakeven | 92.1% | 32.4% |
| Time to Breakeven | 56 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -32.1% | -33.7% |
| % Gain to Breakeven | 47.2% | 50.9% |
| Time to Breakeven | 5 days | 140 days |
In The Past
Beyond Air's stock fell -37.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 59.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Beyond Air (XAIR)
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of persistent pulmonary hypertension of the newborn; acute viral pneumonia, including COVID-19; bronchiolitis and nontuberculous mycobacteria lung infections; and solid tumors. It operates in Israel, Ireland, Australia, and the European Union. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
AI Analysis | Feedback
Here are 1-3 brief analogies for Beyond Air (XAIR):
- Like Inogen, but for therapeutic nitric oxide instead of oxygen.
- Like Moderna, but focused on a nitric oxide generation and delivery platform for various medical treatments, instead of mRNA.
AI Analysis | Feedback
- LungFit system: A nitric oxide (NO) generator and delivery system currently in clinical trials for treating conditions such as persistent pulmonary hypertension of the newborn, acute viral pneumonia, bronchiolitis, nontuberculous mycobacteria lung infections, and solid tumors.
AI Analysis | Feedback
Beyond Air, Inc. (XAIR) is a clinical-stage medical device and biopharmaceutical company. Its primary product, the LungFit system, is currently in clinical trials for various medical conditions.As a clinical-stage company, Beyond Air, Inc. does not yet have commercialized products available for sale. Therefore, it does not currently have major customers, either companies or individuals, purchasing its products to generate revenue.
The company's current activities are focused on research, development, and conducting clinical trials, rather than commercial sales.
AI Analysis | Feedback
nullAI Analysis | Feedback
Management Team
Steve Lisi, Chief Executive Officer and Board Director
Mr. Lisi has served on Beyond Air's Board since January 2017 and as CEO since June 2017. Previously, he was Senior Vice President of Business and Corporate Development at Avadel Pharmaceuticals (AVDL), where he was instrumental in restructuring the company, raising over $125 million, and transforming it from a $100 million enterprise value to $1 billion in three years. Prior to Avadel, Mr. Lisi spent 18 years investing in the global healthcare industry at firms such as Deerfield Management, Millennium Management, and SAC Capital. He is also the Chairman of the Board of Beyond Cancer, an immuno-oncology company focused on solid tumors.
Dan Moorhead, Chief Financial Officer
Mr. Moorhead was appointed Chief Financial Officer, effective January 5, 2026. He brings over 20 years of finance leadership experience across public and private companies. Prior to joining Beyond Air, Mr. Moorhead served as Chief Financial Officer of Zynex, Inc., a publicly traded medical device company, from June 2017 to August 2025. Before his time at Zynex, he spent ten years at Evolving Systems, Inc., where he eventually became CFO. Mr. Moorhead is a CPA and holds a B.B.A. in Accounting from the University of Northern Colorado.
Michael Gaul, Chief Operating Officer
Mr. Gaul serves as the Chief Operating Officer of Beyond Air.
Frederick Montgomery, PhD, Vice President, Medical Systems
Dr. Montgomery is the Vice President, Medical Systems at Beyond Air.
John Jett, PhD, Head of Research and Clinical Development
Dr. Jett serves as the Head of Research and Clinical Development for Beyond Air.
AI Analysis | Feedback
The key risks to Beyond Air's business include its significant financial challenges and cash burn, the complexities of market adoption and intense competition, and the inherent uncertainties and potential delays in regulatory approvals for its products.Key Risks to Beyond Air (XAIR)
- Financial Challenges and Cash Burn: Beyond Air faces significant financial hurdles, including substantial cash burn and recurring net losses. The company has burned through approximately $56 million in fiscal year 2024 and reported a net loss of $46.6 million in FY2025. This heavy cash consumption raises concerns about its ability to fund ongoing operations, product development, and commercialization efforts. Despite capital raises aimed at extending its cash runway, the company's financial health remains highly dependent on external funding and successful market penetration to achieve cash flow breakeven.
- Market Adoption and Competitive Pressures: The success of Beyond Air's LungFit system hinges on its acceptance by healthcare providers and its ability to compete effectively in a market dominated by established players. Mallinckrodt, for example, holds a significant market share (70%) in the nitric oxide delivery systems market. Beyond Air faces challenges in convincing customers to switch to its innovative system, and slow hospital onboarding can constrain revenue growth. This competitive landscape and the need for broad market adoption pose substantial risks to the company's commercial success.
- Regulatory Delays and Approval Uncertainties: As a medical device and biopharmaceutical company, Beyond Air's progress is highly dependent on obtaining and maintaining regulatory approvals for its products. Any setbacks, delays, or challenges in securing FDA approvals for next-generation LungFit systems or label expansions for new indications, as well as obtaining CE marking in Europe, could significantly delay market entry and impact revenue projections. The regulatory environment is complex and plays a crucial role in the company's future.
AI Analysis | Feedback
nullAI Analysis | Feedback
Addressable Markets for Beyond Air (XAIR) Products and Services
- LungFit system for Persistent Pulmonary Hypertension of the Newborn (PPHN): The global addressable market for PPHN is estimated to be a $700 million opportunity.
- LungFit system for Acute Viral Pneumonia (including COVID-19): The global acute respiratory infection market, which encompasses acute viral pneumonia, was valued at approximately USD 17.8 billion in 2023 and is projected to grow to around USD 20.3 billion by 2032.
- LungFit system for Bronchiolitis: The global bronchiolitis drugs market was valued at USD 58.62 million in 2021 and is expected to reach USD 83.37 million by 2029.
- LungFit system for Nontuberculous Mycobacteria (NTM) Lung Infections: The global nontuberculous mycobacterium treatment market size was valued at USD 9.8 billion in 2025 and is projected to reach USD 12.8 billion by the end of 2035. The NTM market across the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) is forecast to grow from $2.0 billion in 2023 to $4.6 billion in 2033.
- LungFit system for Solid Tumors: The global solid tumors market size was valued at USD 362.21 billion in 2024 and is projected to reach USD 1557.42 billion by 2032.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Beyond Air (XAIR)
Beyond Air (NASDAQ: XAIR) is anticipated to drive future revenue growth over the next 2-3 years through several key initiatives focused on its LungFit system.
- Increased Adoption and Commercialization of LungFit PH System: Beyond Air expects continued revenue growth from the increasing adoption and commercialization of its LungFit PH system. The company has reported sequential revenue growth and a significant increase in hospital clients, driven by enhanced marketing and customer education programs. An upgraded LungFit PH system, including a key software update, is also expected to meet accelerating demand.
- FDA Approval and Launch of the Next-Generation LungFit PH II System: The anticipated FDA approval of the second-generation LungFit PH II system is a significant driver. This new system is designed to be smaller, lighter, and fully transport-ready, addressing a primary limitation of the first-generation device. This improvement is expected to open up the entire nitric oxide (NO) market and boost the company's market presence upon its expected approval by year-end (calendar year 2026).
- Expansion of LungFit PH Label to Include Cardiac Surgery: Beyond Air has submitted a PMA supplement to the FDA for the expansion of the LungFit PH label to include cardiac surgery. The acceptance and substantive review of this supplement are expected to positively impact revenues, broadening the addressable market for the LungFit PH system. This impact is anticipated in the latter half of fiscal year 2025 and beyond.
- International Expansion of LungFit PH: The company is actively pursuing international expansion for its LungFit PH system. Beyond Air is expanding its global footprint with partnerships in 40 countries and aims to generate revenue in 12 countries by the end of calendar year 2026. Recent distribution agreements include key markets such as Germany, Brazil, Austria, the Netherlands, and Sri Lanka.
AI Analysis | Feedback
Share Issuance
- In January 2026, Beyond Air entered a private placement to sell 3,930,818 shares of common stock (or pre-funded warrants) and warrants for approximately $5.0 million in gross proceeds.
- In November 2025, the company secured an Equity Line of Credit (ELOC) agreement with Streeterville Capital, allowing them to sell up to $20 million of newly issued common stock over a 24-month period.
- In July 2025, Beyond Air implemented a 1-for-20 reverse stock split to raise its per-share bid price above $1.00 and regain compliance with Nasdaq listing rules.
Inbound Investments
- In November 2025, Beyond Air issued a $12.0 million promissory note to Streeterville Capital, bearing a 15% annual interest rate.
- In January 2026, Beyond Air announced a binding agreement to sell 85% of its NeuroNOS subsidiary to XTL Biopharmaceuticals Ltd., expecting to receive $1 million in cash and up to $31.5 million in milestone-based contingent payments.
- Subsequent to December 31, 2025, the company completed an additional $4.5 million equity financing.
Capital Expenditures
- Capital expenditures were reported as -$1.98 million in the last 12 months.
- Investing cash flow (capital expenditures) was reported as ($2.48 million) over the last twelve months.
- The primary focus of capital expenditures is on the development and commercialization of its LungFit PH system, including the anticipated launch of its second-generation LungFit PH prior to the end of calendar 2026.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Beyond Air Earnings Notes | 12/16/2025 | |
| With Beyond Air Stock Sliding, Have You Assessed The Risk? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to XAIR.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 193.23 |
| Mkt Cap | 19.8 |
| Rev LTM | 3,532 |
| Op Inc LTM | 1,115 |
| FCF LTM | 145 |
| FCF 3Y Avg | 89 |
| CFO LTM | 1,054 |
| CFO 3Y Avg | 875 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.2% |
| Rev Chg 3Y Avg | 1.3% |
| Rev Chg Q | 9.8% |
| QoQ Delta Rev Chg LTM | 2.3% |
| Op Inc Chg LTM | 13.0% |
| Op Inc Chg 3Y Avg | 15.2% |
| Op Mgn LTM | 22.7% |
| Op Mgn 3Y Avg | 18.6% |
| QoQ Delta Op Mgn LTM | 0.5% |
| CFO/Rev LTM | 22.5% |
| CFO/Rev 3Y Avg | 20.6% |
| FCF/Rev LTM | 11.6% |
| FCF/Rev 3Y Avg | 7.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 19.8 |
| P/S | 5.4 |
| P/Op Inc | 23.3 |
| P/EBIT | 22.8 |
| P/E | 15.2 |
| P/CFO | 16.2 |
| Total Yield | 4.9% |
| Dividend Yield | 0.6% |
| FCF Yield 3Y Avg | 1.9% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -3.8% |
| 3M Rtn | -4.4% |
| 6M Rtn | 2.3% |
| 12M Rtn | -1.6% |
| 3Y Rtn | -6.3% |
| 1M Excs Rtn | -13.6% |
| 3M Excs Rtn | -9.4% |
| 6M Excs Rtn | -3.6% |
| 12M Excs Rtn | -30.3% |
| 3Y Excs Rtn | -82.5% |
Price Behavior
Price Behavior
| Market Price | $0.58 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/16/2018 | |
| Distance from 52W High | -89.8% | |
| 50 Days | 200 Days | |
| DMA Price | $0.71 | $1.57 |
| DMA Trend | down | down |
| Distance from DMA | -18.3% | -63.2% |
| 3M | 1YR | |
| Volatility | 97.9% | 196.8% |
| Downside Capture | 1.28 | 0.38 |
| Upside Capture | -109.48 | -181.16 |
| Correlation (SPY) | 16.7% | 0.8% |
XAIR Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.53 | 1.08 | 1.12 | 0.20 | 0.15 | 0.87 |
| Up Beta | 2.96 | 3.26 | 3.22 | 2.69 | 1.66 | 0.98 |
| Down Beta | 5.59 | -1.85 | -1.55 | 2.42 | 1.27 | 1.34 |
| Up Capture | -155% | -115% | -94% | -127% | -57% | -6% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 11 | 20 | 26 | 45 | 104 | 321 |
| Down Capture | 480% | 267% | 256% | 98% | 97% | 111% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 11 | 23 | 35 | 77 | 136 | 406 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with XAIR | |
|---|---|---|---|---|
| XAIR | -85.8% | 196.5% | -0.33 | - |
| Sector ETF (XLV) | 6.8% | 15.7% | 0.23 | -2.1% |
| Equity (SPY) | 27.8% | 12.5% | 1.73 | 1.0% |
| Gold (GLD) | 40.6% | 27.2% | 1.23 | 4.9% |
| Commodities (DBC) | 50.1% | 18.0% | 2.16 | 5.8% |
| Real Estate (VNQ) | 11.0% | 13.4% | 0.53 | 1.3% |
| Bitcoin (BTCUSD) | -17.3% | 42.2% | -0.34 | 13.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with XAIR | |
|---|---|---|---|---|
| XAIR | -65.7% | 121.7% | -0.38 | - |
| Sector ETF (XLV) | 5.2% | 14.6% | 0.18 | 8.7% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 13.3% |
| Gold (GLD) | 20.2% | 17.9% | 0.92 | 4.9% |
| Commodities (DBC) | 14.0% | 19.1% | 0.60 | 2.2% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.09 | 12.4% |
| Bitcoin (BTCUSD) | 7.9% | 56.2% | 0.35 | 15.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with XAIR | |
|---|---|---|---|---|
| XAIR | -40.5% | 111.9% | -0.20 | - |
| Sector ETF (XLV) | 9.2% | 16.5% | 0.45 | 8.5% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 12.6% |
| Gold (GLD) | 13.4% | 15.9% | 0.70 | 6.9% |
| Commodities (DBC) | 9.6% | 17.7% | 0.45 | 4.7% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 9.5% |
| Bitcoin (BTCUSD) | 67.4% | 66.9% | 1.06 | 14.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/13/2026 | 2.9% | -3.8% | -23.3% |
| 11/14/2025 | -2.9% | -5.1% | -31.8% |
| 6/18/2025 | 14.6% | -19.3% | -16.0% |
| 2/14/2025 | -6.7% | -16.5% | -27.1% |
| 11/18/2024 | 3.1% | 7.3% | -15.4% |
| 6/27/2024 | -7.4% | 1.7% | 6.6% |
| 2/16/2024 | 2.6% | -6.7% | -21.1% |
| 11/17/2023 | 6.0% | 5.3% | 13.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 7 | 5 |
| # Negative | 9 | 10 | 12 |
| Median Positive | 4.2% | 5.3% | 13.3% |
| Median Negative | -2.9% | -7.3% | -18.7% |
| Max Positive | 14.6% | 63.8% | 33.8% |
| Max Negative | -7.7% | -19.3% | -33.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/13/2026 | 10-Q |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 06/20/2025 | 10-K |
| 12/31/2024 | 02/10/2025 | 10-Q |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 06/24/2024 | 10-K |
| 12/31/2023 | 02/12/2024 | 10-Q |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 06/22/2023 | 10-K |
| 12/31/2022 | 02/10/2023 | 10-Q |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 06/29/2022 | 10-K |
Recent Forward Guidance [BETA]
Latest: Q3 2026 Earnings Reported 2/13/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 8.00 Mil | 9.00 Mil | 10.00 Mil | 0 | Affirmed | Guidance: 9.00 Mil for 2026 | |
| 2026 NeuroNOS Transaction Proceeds | 32.50 Mil | ||||||
Prior: Q2 2026 Earnings Reported 11/14/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 8.00 Mil | 9.00 Mil | 10.00 Mil | -35.7% | Lowered | Guidance: 14.00 Mil for 2026 | |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lisi, Steven A | CEO and Chairman of the Board | Direct | Buy | 7232025 | 3.25 | 6,000 | 19,491 | 10,809,095 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.